Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PL-3994

Other · developed by Palatin Technologies

Phase 2 Most advanced trial (none active)

PTN Developer

3 Registered trials

What is PL-3994?

PL-3994 is an investigational drug studied in Hypertension, Asthma, Heart Failure With Preserved Ejection Fraction.

At a glance

Drug type: Other
Therapy area: Cardiovascular, Respiratory
Developer: Palatin Technologies, Inc (PTN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: YI2S0GUQ2C

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04318145	Phase 2	Heart Failure With Preserved Ejection Fraction	Terminated	PTN
NCT00686803	Phase 2	Hypertension	Completed	PTN
NCT01304628	Phase 2	Asthma	Withdrawn	PTN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AsthmaHeart Failure With Preserved Ejection FractionHypertension

More from Palatin Technologies

PL8177 Phase 2 PL9643 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the PTN page.

Follow PTN, the company behind PL-3994

See PTN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z